Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation
Kurt Bestehorn(MSD (Germany)), J Weinreich(Roche (Switzerland)), T Volmer, Gerd Glaeske(University of Bremen), Oliver Schöffski(Friedrich-Alexander-Universität Erlangen-Nürnberg), Reiner Leidl(Institute of Groundwater Ecology), Karl W. Lauterbach(Harvard University), A. Kilburg(Institute of Empirical Health Economics), Johanna Graf(Leibniz University Hannover), Michael Köhler(Boehringer Ingelheim (Germany)), Johannes Clouth(Eli Lilly (Germany)), R Rychlik(Institute of Empirical Health Economics), M. Biller(Landschaftsverband Westfalen-Lippe), G. Hartmann(Volkswagen Group (United States)), Kristyn Kamke(National Association of Statutory Health Insurance Physicians), Petra Thürmann(Witten/Herdecke University), Josef Georg Brecht, Christian Naujoks(Novartis (France)), O Mast(Bayer (Germany)), Wolfgang Greiner(Bielefeld University), Frank-Ulrich Fricke(Novartis (France)), Kristina M. Adams Waldorf(University of Washington)
Cited by 63
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465